Immunotherapy has revolutionized the treatment landscape for many cancers, including high-risk, early-stage breast cancers. Despite its transformative potential, immunotherapy has shown limited efficacy in tumor reduction for breast cancer patients, highlighting the urgent need for novel biomarkers that can predict and enhance therapeutic success. In a groundbreaking study published recently, researchers at the Vanderbilt-Ingram Cancer Center have identified a promising approach that leverages liquid biopsies via repeated blood sampling to dynamically assess the antitumor immune response during treatment.
This innovative approach centers on transcriptomic profiling of peripheral blood samples, providing a minimally invasive and cost-effective alternative to conventional tissue biopsies. By analyzing RNA sequences from the blood, the researchers could capture the immune system’s evolving reaction to therapy, offering a window into how tumors and immune cells interact over time. This technique not only circumvents the complications of surgical biopsies but also promises real-time insights that could inform personalized treatment regimens.
The study enrolled 160 patients diagnosed with high-risk, stage 2 or 3 breast cancers that were negative for the human epidermal growth factor receptor 2 (HER2). These patients received either chemotherapy alone or in combination with the immunotherapy agent pembrolizumab. From this cohort, 546 peripheral blood samples were collected longitudinally, enabling the team to perform comprehensive RNA sequencing and analyze the gene expression profiles correlated with immune activity.
A key focus of the research was on characterizing the transcriptional signatures of T cells—critical components of the adaptive immune system responsible for targeting and destroying cancer cells. By examining the clonal expansion and activation markers of these T cells in patients’ blood, the investigators could predict responses to pembrolizumab with remarkable accuracy. This approach hints at the possibility of using blood-based transcriptome profiles as predictive biomarkers for immunotherapy outcomes.
The corresponding author of the study, Dr. Justin Balko, emphasized the collaborative nature of this research, which involved multiple investigators from the nationwide I-SPY2 clinical trial network. Patients enrolled in this adaptive trial provided the indispensable blood samples that powered the analyses. The I-SPY2 trial itself is a pioneering initiative designed to tailor breast cancer treatments based on molecular characteristics, enabling precision medicine approaches to improve patient outcomes across diverse subtypes.
What distinguishes this liquid biopsy method is its ability to monitor complex immune responses over the course of treatment. Traditional biopsies provide a static snapshot of tumor biology, whereas serial blood sampling can reveal dynamic immunological changes. This temporal resolution is crucial for understanding mechanisms of resistance or sensitivity to therapy and allows for adaptive treatment modifications that could enhance efficacy.
Current clinical liquid biopsy paradigms primarily focus on cell-free DNA, which has proven valuable for mutation detection and tracking tumor burden across various cancers. However, this study’s focus on RNA sequencing expands the utility of liquid biopsies, offering insights into gene expression patterns that govern immune cell function rather than just genetic alterations in tumor cells.
The research team also highlighted the translational potential of their findings beyond breast cancer. Similar immune transcriptomic profiling could be applied to other solid tumors where immunotherapy is being explored. Such advancements herald a new era of precision oncology, where minimally invasive blood tests guide treatment decisions tailored to each patient’s unique tumor-immune interplay.
While these findings are promising, the authors acknowledge the necessity for further validation in larger clinical cohorts. Confirmatory studies are essential to establish standardized protocols for blood-based RNA sequencing and to integrate these biomarkers into routine clinical workflows. Nonetheless, this research lays a vital foundation for future efforts aiming to harness the immune system’s power more effectively.
The first author, Dr. Xiaopeng Sun, who recently transitioned to Merck, along with co-authors including graduate students Andres Ocampo, Jacey Marshall, and Julia Steele, as well as senior research supervisor Dr. Susan Opalenik, contributed significant expertise. Their combined efforts demonstrate how collaborative scientific inquiry can pave the way for innovative cancer diagnostics.
This study was supported by a robust funding portfolio including grants from the National Institutes of Health, the Department of Defense Era of Hope Award, the Breast Cancer Research Foundation, Stand Up To Cancer, and the California Breast Cancer Research Program. Such financial backing underscores the critical importance of advancing breast cancer research and the high expectations for liquid biopsy technologies in oncology.
The implications of this research are profound, offering a path to more personalized, adaptive immunotherapy regimens. As we move towards an era where treatment is continuously refined based on a patient’s biological responses, liquid biopsies that capture immune transcriptional dynamics will likely become indispensable tools for clinicians. This could dramatically improve survival and quality of life for breast cancer patients facing high-risk diseases.
Subject of Research: Transcriptomic profiling of peripheral blood to predict response to neoadjuvant chemoimmunotherapy in high-risk breast cancer
Article Title: Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer
News Publication Date: 22-Apr-2026
Web References:
http://dx.doi.org/10.1126/scitranslmed.aec2358
References:
Study published in Science Translational Medicine, DOI: 10.1126/scitranslmed.aec2358
Keywords: Breast cancer, immunotherapy, liquid biopsy, RNA sequencing, peripheral blood transcriptome, pembrolizumab, T cells, I-SPY2 clinical trial, precision oncology, neoadjuvant therapy, transcriptomic biomarkers
